Slide 1: Investor Presentation Q3FY26
Investor Presentation Q3FY26 23-01-2026 1
Slide 2: Disclaimer
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: India Business Back on Strong Double-digit Growth Trajectory
India Business Back on Strong Double-digit Growth Trajectory Revenue EBITDA PAT 18% 10% Q3FY26 INR 7,074 Cr INR 1,255 Cr of Revenue INR 676 Cr of Revenue Business Performance Snapshot Emerging Markets & One India North America One Africa Europe INR 3,457 Cr $ 167 Mn $ 112 Mn $ 104 Mn Q3FY26 Albutero
Slide 4: Financial Performance – Q3FY26
Financial Performance – Q3FY26 Revenue INR 7,074 Cr EBITDA INR 1,255 Cr Revenue1 Break-up Q3FY26 (Consolidated) API, 2% Others, 1% Actuals vs Q3 FY25 (INR Cr) Emerging Markets & Europe, 13% Total Revenue from 7,074 0.02% Operations EBITDA 1,255 -36.9% One Africa, EBITDA % 17.7% 14% One India, 49% PA
Slide 5: One India - Committed to Sustainable Progress and Enduring Impact
One India1 - Committed to Sustainable Progress and Enduring Impact Delivered a Revenue of INR 3,457 Cr in Q3 FY26 Branded Prescription Trade Generics Consumer Health ❖ Business delivered a strong growth ❖ Delivered a growth of 10% YoY during the quarter ❖ Delivered a robust growth with anchor & tran
Slide 6: India Rx - Strengthening Our Journey with Strategic Therapeutic Focus
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus Steady Uptake in Key Therapies1 Growth (%) Largest pharma company by volume 10.5% (12.4%)2 (units) in market1 Respiratory 10.7% (16.6%)2 Anti-infectives 4.7% 6.2% 4 Brands added in the category of market1 Urology 11.9% revenue > I
Slide 7: One India - Strategic Alliances during the Quarter
One India - Strategic Alliances during the Quarter Pfizer Deal Inzpera Acquisition ❑ Cipla to exclusively market and distribute Pfizer’s key ❑ Cipla acquires 100% stake in Inzpera Healthsciences, brands (Corex, Dolonex, Neksium, Dalacin C) in India adding a differentiated paediatric and wellness por
Slide 8: Launched India's First Dedicated Lung Diagnostics & Wellness Center in Delhi
Launched India’s First Dedicated Lung Diagnostics & Wellness Center in Delhi • Over 50 doctors have visited the facility to explore the center • Several patients diagnosed for various panels within the first 6 weeks of launch • Comprehensive panel testing for Asthma, COPD, and ILD conducted for the
Slide 9: Q3 FY26 - Global Consumer Wellness Franchise
Q3 FY26 - Global Consumer Wellness Franchise One India One Africa Consumer Brands in 1 One India 2 Revenue: INR 442 Cr Pain Relief Nicotine Replacement Respi OTC Respi OTC 2 2 Consumer Brands in Cold & Cough Skin Infection South Africa Pain Respi OTC Management 2 Revenue: ZAR 354 Mn Pain Hydration M
Slide 10: North America – Adapting to Evolving Business Dynamics
North America – Adapting to Evolving Business Dynamics Key Business Highlights ➢ Albuterol ranked No. 1 with total market1 share at 22% (50 million+ inhaler units supplied to the U.S. market cumulatively) ➢ Lanreotide manufacturing is temporarily paused following USFDA observations at our partner Ph
Slide 11: ANDA & NDA Portfolio & Pipeline (As on 31st December 2025)
ANDA & NDA Portfolio & Pipeline (As on 31st December 2025) 7 66 9 2 2 97 1 11 23 3 38 23 Approved Tentatively Under Approval ANDAs & NDAs Approved ANDAs & NDAs ANDAs & NDAs 1 Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs 179 49 54 282 Approved Tentatively Under Approval Total ANDAs & NDAs Approved A
Slide 12: One Africa - South Africa Private Growing Faster than the Market
One Africa1 - South Africa Private Growing Faster than the Market ZAR Mn SA Private Revenue trend ZAR Mn SA Private Revenue Trend 14 15 10 9 24 20 1,196 1,156 1,106 67 68 Q3FY25 Q3FY26 Q3FY24 Q3FY25 Q3FY26 SA Private SA Tender North Africa Others (SSA & CGA) Market Segment 2 Rank Share Cipla Growth
Slide 13: Q3 FY26 - Emerging Markets & Europe and API
Q3 FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API Revenue Revenue 104 16 98 15 Q3FY25 Q3FY26 Q3FY25 Q3FY26 13
Slide 14: Our ESG Roadmap: Near-Term & Long-Term Goals
Our ESG Roadmap : Near-Term & Long-Term Goals Pillar Aspects Near-Term 2030 Goals Renewable Electricity share 80% for India manufacturing GHG Emission 1. 30% Absolute reduction (Scope-1 energy based and Scope -2) from baseline of FY 2024 for Global Cipla (Scope-1 & 2) 2. Build capacity infrastructur
Slide 15: Consolidated Profit and Loss Statement Summary
INR Cr Consolidated Profit and Loss Statement Summary Particulars Q3 FY26 Q3 FY25 Revenue from sale of products 6,963 6,962 Other operating income 112 111 Income from operations 7,074 7,073 Material cost 2,632 2,264 Employee benefits expense 1,325 1,198 Other expenses 1,862 1,622 Total expenses 5,81
Slide 16: Consolidated Balance Sheet
Consolidated Balance Sheet INR Cr Key Balance Sheet Items Dec-25 Dec-24 Equity 33,913 30,012 Total Debt# 489 466 Inventory 6,268 5,562 Cash and Cash Equivalents* 10,718 9,413 Trade Receivables 6,230 5,858 Trade Payables 3,254 2,764 Net Tangible Assets 7,213 6,372 Goodwill and Intangibles 5,679 4,984
Slide 17: Thank You
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 17